Drugs News and Research

RSS

Abbott's Tacrolimus assay provides consistent medication monitoring for organ transplant patients

A new study published in the journal Clinical Chemistry reported Abbott's ARCHITECT Tacrolimus assay provides accurate and consistent medication monitoring for patients taking tacrolimus, an immunosuppressive medication, after receiving solid organ transplantation.

14 Feb 2012

Scientists create fungi with additional foreign genes to produce chemicals for drugs

Usually, mould fungi are nothing to cheer about - but now they can be used as "chemical factories". Scientists at the Vienna University of Technology have succeeded in introducing bacterial genes into the fungus Trichoderma, so that the fungus can now produce important chemicals for the pharmaceutical industry. The raw material used by the fungus is abundant - it is chitin, which makes up the shells of crustaceans.

14 Feb 2012

Stress protein effectively activates replication of HBV in liver cells

People who have received a donor organ need lifelong immunosuppressant drugs to keep their immune system from attacking the foreign tissue. However, with a suppressed immune system, many infectious agents turn into a threat. Infections such as with human cytomegalovirus and a certain type of human polyomavirus frequently cause complications in transplant recipients.

14 Feb 2012

Viewpoints: Rationing health care, Jindal and hospitals, Romney vs. past

It is time to begin open discussions about how to deal with expensive, minimally effective, medical care with patients, families, professionals and ethicists and not the medical industrialists who gain from prolonging life at every expense.

14 Feb 2012

Large NTD public-private partnership has greater potential than smaller efforts

The announcement at the end of January of the largest coordinated effort to fight neglected tropical diseases (NTDs) provides "more reason to hope that we may soon see a future free of these diseases," Adetokunbo Lucas, former director of the UNICEF/UNDP/World Bank/WHO Special Programme for Research and Training in Tropical Diseases, writes in a Daily Monitor opinion piece.

14 Feb 2012

Fresh insights into cell division could help scientists develop cancer drugs

Fresh insights into how our cells multiply could help scientists develop drugs to treat cancer. Researchers have gained better understanding of the workings of two key proteins that control cell division. This process must be carried out accurately to keep cells healthy, and when it goes out of control, it can lead to cancer.

14 Feb 2012

FDA requests a budget of $4.5 billion to protect and promote public health

The U.S. Food and Drug Administration is requesting a budget of $4.5 billion to protect and promote the public health as part of the President's fiscal year (FY) 2013 budget – a 17 percent increase over the FDA enacted budget for FY 2012.

14 Feb 2012

Fair trade agreement between E.U., India could impede access to medicine for world's poor

"Current negotiations on a free trade agreement (FTA) between the European Union and India are causing serious concern in many quarters over future access to cheap generic medicines used to treat some of the world's great public health threats: HIV, tuberculosis and malaria, and also cancer," Philippe Douste-Blazy, U.N. special adviser on innovative financing for development and chair of UNITAID, and Denis Broun, executive director of UNITAID, write in this post in the Guardian's "Poverty Matters Blog."

14 Feb 2012

Radiation induces testicular cancer in male fetuses

Male fetuses of mothers that are exposed to radiation during early pregnancy may have an increased chance of developing testicular cancer, according to a study in mice at The University of Texas MD Anderson Cancer Center.

14 Feb 2012

Scientists create new mouse model for medulloblastoma

Scientists at Sanford-Burnham Medical Research Institute (Sanford-Burnham) developed a new mouse model for studying a devastating childhood brain cancer called medulloblastoma.

14 Feb 2012

FDA accepts Gilead's Truvada sNDA and grants Priority Review

Gilead Sciences, Inc. announced today that the U.S. Food and Drug Administration (FDA) has accepted the supplemental New Drug Application (sNDA) and granted a six-month Priority Review for once-daily Truvada (emtricitabine/tenofovir disoproxil fumarate) for pre-exposure prophylaxis (PrEP) to reduce the risk of HIV-1 infection among uninfected adults.

14 Feb 2012

CyBorD regimen shows promise against AL amyloidosis

A Mayo Clinic-led study, published in the American Society of Hematology (ASH) journal Blood found that CyBorD, a triple chemotherapy drug combination that has been successful in helping patients with the blood cancer multiple myeloma, also showed promise in improving the care for patients with the rare blood disease AL amyloidosis.

14 Feb 2012

Norwegian government introduces legal limits for 20 illegal drugs and medicines

Legal limits for twenty illegal drugs and medicines with an abuse potential have been introduced by the Norwegian government. Norway is the first country to define both impairment-based legislative limits and limits for graded sanctions for drugs other than alcohol. The Norwegian Institute of Public Health participated to provide the scientific basis for the new limits.

14 Feb 2012

Scientists identify more than 100 new cases of alkaptonuria

Scientists at the University of Liverpool, working with international partners, have shown a rare genetic disease, that causes crippling osteoarthritis in the spine and major joints, is far more prevalent worldwide than previously thought.

14 Feb 2012

Internet addiction, shyness, defiance and grief on bereavement could be mental disorders – Debate on proposed DSM-5

The American Psychiatric Association (APA) has attracted a lot of debate on its proposed amendments to its newest Diagnostic and Statistical Manual of Mental Disorders (DSM) the outlines psychiatric symptoms in the mental-health industry.

13 Feb 2012

Chemotherapy during pregnancy for cancer does not necessarily harm the baby: Study

When a pregnant woman is diagnosed with cancer, she and her family and doctors are faced with difficult decisions about her health and that of her unborn child. It is known that giving chemotherapy in the first 12 weeks, when the baby's organs are still forming, raises the chances of birth defects. Postponing the treatment, however, could allow the cancer to spread. Over the last decade, doctors have been more willing to use chemotherapy after the first trimester, but there have been worries that the child's brain and heart could suffer damage.

13 Feb 2012

Cannabis and automobile accidents: Analysis finds link

A new Canadian study suggests that drivers who use cannabis up to three hours before driving are twice as likely to cause a collision as those not under the influence of drugs or alcohol. The researchers say that this is because cannabis impairs brain and motor functions needed for safe driving. The study in bmj.com reviewed nine studies of 50,000 people worldwide who had been in serious or fatal crashes.

13 Feb 2012

Discovery of novel rearrangements and fusions supports role for NGS in treatment of cancer

Foundation Medicine, Inc., a molecular information company that brings comprehensive cancer gene analysis to routine clinical care, and Dana-Farber Cancer Institute today announced the Nature Medicine publication of results from their collaborative next-generation sequencing (NGS) study to assay cancer-relevant genes in 24 non-small cell lung cancer (NSCLC) and 40 colorectal cancer (CRC) cases.

13 Feb 2012

Trevena commences TRV130 Phase I clinical trial for severe post-operative pain

Trevena, Inc., the leader in discovery and development of G-protein coupled receptor (GPCR) biased ligands, announced today the initiation of a Phase I clinical trial of TRV130, a novel candidate designed for the intravenous treatment of moderate-to-severe post-operative pain.

13 Feb 2012

NTRR completes research and development of new erectile dysfunction treatment

With Neutra Corp.'s Pure Plus weight-loss supplement already in the midst of clinical trials, the company announced today that it has completed research and development of its next product in the Pure Plus line: an all-natural erectile dysfunction (ED) treatment.

13 Feb 2012